ArticleNeurodegenerative disease management
Practices and perceptions around splitting of carbidopa/levodopa tablets: a survey of patients and neurologists.
Article in Neurodegenerative disease management. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCarbidopa/levodopa (CD/LD) remains the primary treatment for Parkinson's disease (PD) motor control symptoms. With progressing disease, for better symptom management, patients often split immediate-release CD/LD tablets-research on this practice is limited.
objectiveSurvey patients with PD/caregivers, and neurologists on CD/LD pill-splitting practices and motor complications' impact on quality of life (QoL).
methodsWe surveyed 101 patients/caregivers and 120 neurologists.
resultsAll agreed that motor control symptoms substantially affect QoL, particularly as PD progresses. 47% of patients surveyed halved immediate-release CD/LD tablets, and 27% fragmenting them further, with 27% and 18% finding it easy and accurate, respectively. Pill splitters reported longer disease duration, more advanced PD, worse motor fluctuations/dyskinesia control, and QoL. Neurologists reported dissatisfaction with CD/LD treatments for advanced disease, noting 44.9% of patients split tablets with, and 21.9% without, physician recommendation.
conclusionsPill splitting is common but burdensome and imprecise. Further research is needed to evaluate clinical impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.